Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jeffrey Wolf

Showing results (21-30 of 80) with videos related to

Pageof 8
Sort By:
Immunotherapy|October 17, 2025
How should we choose optimal salvage treatments following BCMA-directed CAR T-cell therapy?Arvind Suresh, Darren Pan, Jodi Lipof, et al.
Frontiers in Oncology|December 23, 2021
Early Dynamics and Depth of Response in Multiple Myeloma Patients Treated With BCMA CAR-T CellsSandy W Wong, Nina Shah, Guy Ledergor, et al.
Head & Neck|June 2, 2009
Patterns of failure among patients with squamous cell carcinoma of the head and neck who obtain a complete response to chemoradiotherapySusannah Yovino, Kathleen Settle, Rodney Taylor, et al.
Blood Advances|October 13, 2021
Macrophage activation syndrome-like (MAS-L) manifestations following BCMA-directed CAR T cells in multiple myelomaVanessa E Kennedy, Christopher Wong, Chiung-Yu Huang, et al.
International Journal of Radiation Oncology, Biology, Physics|May 24, 2011
Phase II study evaluating the addition of cetuximab to the concurrent delivery of weekly carboplatin, paclitaxel, and daily radiotherapy for patients with locally advanced squamous cell carcinomas of the head and neckMohan Suntharalingam, Young Kwok, Olga Goloubeva, et al.
Blood Advances|July 25, 2020
Clinical value of measurable residual disease testing for assessing depth, duration, and direction of response in multiple myelomaJoaquin Martinez-Lopez, Sandy W Wong, Nina Shah, et al.
Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners|October 14, 2021
Evaluation of subcutaneous daratumumab injections in the ambulatory care settingAndrew H Tam, Yoonie Jung, Rebecca Young, et al.
Toxicologic Pathology|September 28, 2019
Comparison of Gene Expression Responses in the Small Intestine of Mice Following Exposure to 3 Carcinogens Using the S1500+ Gene Set Informs a Potential Common Adverse Outcome PathwayGrace A Chappell, Julia E Rager, Jeffrey Wolf, et al.
Clinical Lymphoma, Myeloma & Leukemia|March 18, 2014
Deep sequencing reveals myeloma cells in peripheral blood in majority of multiple myeloma patientsRavi Vij, Amitabha Mazumder, Mark Klinger, et al.
Head & Neck|September 20, 2011
Impact of early percutaneous endoscopic gastrostomy tube placement on nutritional status and hospitalization in patients with head and neck cancer receiving definitive chemoradiation therapyCharles E Rutter, Susannah Yovino, Rodney Taylor, et al.
Pageof 8

Showing results (21-30 of 80) with videos related to

Sort By:
Pageof 8
Immunotherapy|October 17, 2025
How should we choose optimal salvage treatments following BCMA-directed CAR T-cell therapy?Arvind Suresh, Darren Pan, Jodi Lipof, et al.
Frontiers in Oncology|December 23, 2021
Early Dynamics and Depth of Response in Multiple Myeloma Patients Treated With BCMA CAR-T CellsSandy W Wong, Nina Shah, Guy Ledergor, et al.
Head & Neck|June 2, 2009
Patterns of failure among patients with squamous cell carcinoma of the head and neck who obtain a complete response to chemoradiotherapySusannah Yovino, Kathleen Settle, Rodney Taylor, et al.
Blood Advances|October 13, 2021
Macrophage activation syndrome-like (MAS-L) manifestations following BCMA-directed CAR T cells in multiple myelomaVanessa E Kennedy, Christopher Wong, Chiung-Yu Huang, et al.
International Journal of Radiation Oncology, Biology, Physics|May 24, 2011
Phase II study evaluating the addition of cetuximab to the concurrent delivery of weekly carboplatin, paclitaxel, and daily radiotherapy for patients with locally advanced squamous cell carcinomas of the head and neckMohan Suntharalingam, Young Kwok, Olga Goloubeva, et al.
Blood Advances|July 25, 2020
Clinical value of measurable residual disease testing for assessing depth, duration, and direction of response in multiple myelomaJoaquin Martinez-Lopez, Sandy W Wong, Nina Shah, et al.
Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners|October 14, 2021
Evaluation of subcutaneous daratumumab injections in the ambulatory care settingAndrew H Tam, Yoonie Jung, Rebecca Young, et al.
Toxicologic Pathology|September 28, 2019
Comparison of Gene Expression Responses in the Small Intestine of Mice Following Exposure to 3 Carcinogens Using the S1500+ Gene Set Informs a Potential Common Adverse Outcome PathwayGrace A Chappell, Julia E Rager, Jeffrey Wolf, et al.
Clinical Lymphoma, Myeloma & Leukemia|March 18, 2014
Deep sequencing reveals myeloma cells in peripheral blood in majority of multiple myeloma patientsRavi Vij, Amitabha Mazumder, Mark Klinger, et al.
Head & Neck|September 20, 2011
Impact of early percutaneous endoscopic gastrostomy tube placement on nutritional status and hospitalization in patients with head and neck cancer receiving definitive chemoradiation therapyCharles E Rutter, Susannah Yovino, Rodney Taylor, et al.
Pageof 8